Abstract：
Cluster of differentiation 36 (CD36) is a multiligand receptor with important roles in lipid metabolism, angiogenesis and innate immunity, and its diverse effects may depend on the binding of specific ligands in different contexts. CD36 is expressed not only on immune cells in the tumor microenvironment (TME) but also on some hematopoietic cells. CD36 is associated with the growth, metastasis and drug resistance in some hematologic tumors, such as leukemia, lymphoma and myelodysplastic syndrome. Currently, some targeted therapeutic agents against CD36 have been developed, such as anti-CD36 antibodies, CD36 antagonists (small molecules) and CD36 expression inhibitors. This paper not only innovatively addresses the role of CD36 in some hematopoietic cells, such as erythrocytes, hematopoietic stem cells and platelets, but also pays special attention to the role of CD36 in the development of hematologic tumors, and suggests that CD36 may be a potential cancer therapeutic target in hematologic tumors.
摘要：
分化簇36（CD36）是一种多配体受体，在脂质代谢中具有重要作用，血管生成和先天免疫，其不同的作用可能取决于特定配体在不同情况下的结合。CD36不仅在肿瘤微环境（TME）中的免疫细胞上表达，而且在某些造血细胞上也表达。CD36与生长有关，一些血液肿瘤的转移和耐药性，比如白血病，淋巴瘤和骨髓增生异常综合征。目前,已经开发了一些针对CD36的靶向治疗剂，如抗CD36抗体，CD36拮抗剂(小分子)和CD36表达抑制剂。本文不仅创新性地探讨了CD36在某些造血细胞中的作用,如红细胞，造血干细胞和血小板,但也特别关注CD36在血液肿瘤发展中的作用，并提示CD36可能是血液肿瘤中潜在的癌症治疗靶点。
